Diagnostic value of PD-1 mRNA expression combined with breast ultrasound in breast cancer patients

被引:3
作者
Fang, Jianhua [1 ]
Shao, Yi [2 ]
Su, Jiezhi [3 ]
Wan, Ying [4 ]
Bao, Lingyun [1 ]
Wang, Wei [1 ]
Kong, Fanlei [1 ]
机构
[1] Hangzhou First Peoples Hosp, Dept Ultrasonog, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China
[2] Nanchang Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanchang 330006, Jiangxi, Peoples R China
[3] Hainan Med Univ, Affiliated Hosp 1, Dept Breast & Chest Surg, Haikou 570102, Hainan, Peoples R China
[4] Hainan Med Univ, Affiliated Hosp 1, Dept Ultrasound, Haikou 570102, Hainan, Peoples R China
关键词
PD-1; breast ultrasound; diagnosis; breast cancer; TUMOR-INFILTRATING LYMPHOCYTES; CARCINOMA IN-SITU; SIGNATURES; PROGNOSIS; ELASTOGRAPHY; BIOMARKER; SURVIVAL; DNA;
D O I
10.2147/TCRM.S168531
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: This study explored the value of measuring programmed death 1 (PD-1) in peripheral blood, combined with breast ultrasound using the Breast Imaging Reporting and Data System (BI-RADS) classification, for differentiation between benign and malignant breast tumors. Materials and methods: We enrolled 113 patients with breast cancer and 66 patients with benign breast tumors who were admitted to Hangzhou First People's Hospital from September 2014 to August 2017. The mRNA level of PD-1 was detected by quantitative real-time polymerise chain reaction. Results: The mRNA levels of PD-1 were significantly higher in the peripheral blood of patients with breast cancer than those in patients with benign breast tumors. The diagnostic sensitivity of PD-1 mRNA expression was 0.805, the specificity was 0.788, and the area wider the curve (AUC) was 0.848 (P < 0.001); the sensitivity of breast ultrasound-based BI-RADS classification was 0.752, the specificity was 0.909, and the AUC was 0.906 (P < 0.001); and the combined sensitivity, specificity, and AUC of the two assays were 0.920, 0.879, and 0.938, respectively (P < 0.001). Progesterone receptor-positive breast cancer patients exhibited high levels of PD-1 expression (P < 0.001). Conclusion: This study suggests that the measurement of PD-1 combined with breast ultrasound-based BI-RADS classification represents a significant improvement for breast cancer diagnosis compared with diagnoses based on either method alone.
引用
收藏
页码:1527 / 1535
页数:9
相关论文
共 50 条
[1]  
[Anonymous], ANN BIOMED ENG
[2]   Predictive values of BI-RADS® magnetic resonance imaging (MRI) in the detection of breast ductal carcinoma in situ (DCIS) [J].
Badan, Gustavo Machado ;
Piato, Sebastiao ;
Roveda Junior, Decio ;
Castro Fleury, Eduardo de Faria .
EUROPEAN JOURNAL OF RADIOLOGY, 2016, 85 (10) :1701-1707
[3]   Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome [J].
Beckers, Rhiannon K. ;
Selinger, Christina I. ;
Vilain, Ricardo ;
Madore, Jason ;
Wilmott, James S. ;
Harvey, Kate ;
Holliday, Anne ;
Cooper, Caroline L. ;
Robbins, Elizabeth ;
Gillett, David ;
Kennedy, Catherine W. ;
Gluch, Laurence ;
Carmalt, Hugh ;
Mak, Cindy ;
Warrier, Sanjay ;
Gee, Harriet E. ;
Chan, Charles ;
McLean, Anna ;
Walker, Emily ;
McNeil, Catriona M. ;
Beith, Jane M. ;
Swarbrick, Alexander ;
Scolyer, Richard A. ;
O'Toole, Sandra A. .
HISTOPATHOLOGY, 2016, 69 (01) :25-34
[4]   The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers [J].
Bertucci, Francois ;
Finetti, Pascal ;
Birnbaum, Daniel ;
Mamessier, Emilie .
ONCOIMMUNOLOGY, 2016, 5 (03)
[5]   BI-RADS 3-5 microcalcifications can preoperatively predict breast cancer HER2 and Luminal a molecular subtype [J].
Cen, DongZhi ;
Xu, Li ;
Li, Ningna ;
Chen, Zhiguang ;
Wang, Lu ;
Zhou, Shuqin ;
Xu, Biao ;
Liu, Chun Ling ;
Liu, Zaiyi ;
Luo, Tingting .
ONCOTARGET, 2017, 8 (08) :13855-13862
[6]   Identification of Circulating MicroRNA Signatures for Breast Cancer Detection [J].
Chan, Maurice ;
Liaw, Chiew Suan ;
Ji, Shen Mo ;
Tan, Hwee Huang ;
Wong, Chow Yin ;
Thike, Aye Aye ;
Tan, Puay Hoon ;
Ho, Gay Hui ;
Lee, Ann Siew-Gek .
CLINICAL CANCER RESEARCH, 2013, 19 (16) :4477-4487
[7]   MMP13 is potentially a new tumor marker for breast cancer diagnosis [J].
Chang, Hui-Jen ;
Yang, Ming-Je ;
Yang, Yu-Hsiang ;
Hou, Ming-Feng ;
Hsueh, Er-Jung ;
Lin, Shiu-Ru .
ONCOLOGY REPORTS, 2009, 22 (05) :1119-1127
[8]   Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study [J].
Chen, Yi ;
Chen, Kai ;
Xiao, Xiaoyun ;
Nie, Yan ;
Qu, Shaohua ;
Gong, Chang ;
Su, Fengxi ;
Song, Erwei .
BMC CANCER, 2016, 16
[9]   Detection of Methylated Circulating DNA as Noninvasive Biomarkers for Breast Cancer Diagnosis [J].
Cheuk, Isabella Wai Yin ;
Shin, Vivian Yvonne ;
Kwong, Ava .
JOURNAL OF BREAST CANCER, 2017, 20 (01) :12-19
[10]   The immune system and hormone-receptor positive breast cancer: Is it really a dead end? [J].
Dieci, Maria Vittoria ;
Griguolo, Gaia ;
Miglietta, Federica ;
Guarneri, Valentina .
CANCER TREATMENT REVIEWS, 2016, 46 :9-19